A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

This study has been completed.
Genzyme, a Sanofi Company
Information provided by:
Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
First received: February 20, 2008
Last updated: March 10, 2008
Last verified: March 2008
This study will look how using taken from your tumors and mixed with special immune stimulating cells from another person's blood in given back to you in a series "fusion cell" injections, will effect your body. The primary goal of the study is to see if giving the experimental fusion cell injections is safe. We will also be looking to see what effect the experimental treatment as on your immune system and whether it has an effect on your cancer.

Condition Intervention Phase
Renal Cell Carcinoma
Biological: Electrofusion DC vaccine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by Beth Israel Deaconess Medical Center:

Primary Outcome Measures:
  • To assess the safety of 3 serial vaccinations with allogeneic DCs: autologous tumor-derived cells subjected to electrofusion in patients with AJCC stage IV RCC [ Time Frame: screening/baseline, treatment period, follow-up and long-term follow-up ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To determine if 3 serial vaccinations of allogeneic DCs: autologous tumor-derived cells subjected to electrofusion will induce a clinical response as assessed by tumor response and will induce an immune response. [ Time Frame: screening/baseline, treatment period, follow-up and long-term follow-up ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: December 2002
Study Completion Date: February 2008
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: Electrofusion DC vaccine
    To assess the safety and efficacy of vaccinations
Detailed Description:
Patients undergo tumor aquisition and short-term tumor cell cultures are established. Leukopheresis is performed monocyte-derived DC are generated ex-vivo by standard culture techniques, utilizing GM-CSF and Il-4. PEG fusions are generated, and following irradiation, the vaccine is frozen. The thawed vaccine is administered SC into a single site every three weeks. Each study is examining a dose-escalating strategy based apon the number PEG-fused generated from the PEG process that expressed both tumor cell and DC markers as determined by immune staining.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient must be _> 18 years of age
  • The patient must be diagnosed with AJCC stage IV (primary or relasped) RCC
  • The patient must have a baseline Eastern Cooperative Oncology Group (ECOG) Clinical performance of 0-1
  • The patient must have accessible tumor (minimum of 2.5cm in diameter in aggregate and accessible) for vaccine production
  • The patient must have measurable tumor lesions (using Response Evaluation Criteria in Solid Tumors (RECIST) following resection of tumor lesions(s) used for vaccine production. If the patient has received previous radiation or intra-tumoral investigational treatments, the measurable disease must be outside the previous radiation port or treatment area unless there is documented tumor progression following the completion of therapy.
  • The patient must have adequate hematologic, hepatic, and renal function parameters within 21 days prior to the first vaccination (day 0 of treatment):

    • White blood cell(WBC) count >_ 3,000 cell/mm3
    • Platelet count >_ 100,000 platelets/mm3
    • Creatine(serum) <2.0mg/dL
    • Total bilirubin <2.0 mg/dL
    • Serum glutamic pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) <2.0 x Upper limits of normal
    • Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) < 2.0 x Upper limits of normal
  • The patient must be serologically negative for human immunodeficiency virus (HIV)-1, HIV-2, and human T lymphotropic virus (HTLV)-1
  • Female patients of childbearing potential must have negative pregnancy tests, refrain from nursing and must agree ton use appropriate contraception for the duration of the trial
  • The patient must have signed and dated written informed consent prior to any study procedures. The consent process must be documented in the patient's medical record

Exclusion Criteria:

  • The patient has received prior chemotherapy
  • The patient's tumor-derived cells do not meet predetermined manufacturing specifications, for example: human leukocyte antigen (HLA) Class 1 molecule expression, sufficient tumor derived cells for vaccine manufacture, or pathologic confirmation of RCC
  • The patient has received more than 2 prior regimes for treatment of RCC and the most recent is within 2 weeks of the first screening procedure
  • The patient has received radiation therapy within 2 weeks of the first sceeening procedure
  • The patient has a clinically significant autoimmune diorder
  • The patient has an active infection at the time of the first screening procedure requiring parenteral antibiotics
  • The patient has clinically significant hematolgic, cardiac, renal, or hepatic disease or any other underlying condition that would contraindicate study therapy or confuse interpretation of study results
  • The patient has any active or clinically significant central nervous system (CNS) metastases
  • The patient has a previous unrelated malignancy or second malignancy within 5 years prior to the first screening procedure, except from non-melanoma skin cancer and in situ carcinomas
  • The patient is receiving chronic immunosuppressive, and/or oral steriod treatment
  • The patient has any other reason in the Investigator's opinion that would make protocol compliance unmanageable or may compromise the patient's ability to give informed consent
  • The patient has been treated with a non-oncologic investigational drug, biologic or medical device within 30 days of the first screening procedure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00625755

United States, Massachusetts
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Genzyme, a Sanofi Company
Principal Investigator: David Avigan, MD Beth Israel Deaconess Medical Center
  More Information

Responsible Party: David Avigan, MD, BIDMC
ClinicalTrials.gov Identifier: NCT00625755     History of Changes
Other Study ID Numbers: 2001-P-001539/4  DCREN-005-01 
Study First Received: February 20, 2008
Last Updated: March 10, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Beth Israel Deaconess Medical Center:
renal cell carcinoma
AJCC Stage IV (primary or relasped) renal cell carcinoma

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Diseases
Kidney Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms

ClinicalTrials.gov processed this record on May 26, 2016